All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

canakinumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
human origin	4952	914613-48-2

Description:

Molecule	Description
Synonyms: canakinumab ilaris ACZ885	a human anti-interleukin-1beta monoclonal antibody for treatment of cryopyrin-associated periodic syndrome Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Drug dosage:

Dose	Unit	Route
2.70	mg	P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

Date	Agency	Company	Orphan
June 17, 2009	FDA	NOVARTIS PHARMS
Oct. 23, 2009	EMA
Sept. 26, 2011	PMDA	Novartis Pharma K.K.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Inappropriate schedule of product administration	878.16	17.85	412	11165	149521	90467349
Haemophagocytic lymphohistiocytosis	429.64	17.85	133	11444	15326	90601544
Pyrexia	364.89	17.85	433	11144	660052	89956818
Incorrect dose administered	195.30	17.85	123	11454	78807	90538063
Serum ferritin increased	137.76	17.85	47	11530	7334	90609536
Interleukin level increased	132.17	17.85	28	11549	694	90616176
Clubbing	118.38	17.85	24	11553	476	90616394
Condition aggravated	116.50	17.85	243	11334	595302	90021568
Illness	114.35	17.85	90	11487	81879	90534991
Serum amyloid A protein increased	109.76	17.85	24	11553	693	90616177
Growth retardation	106.99	17.85	28	11549	1755	90615115
COVID-19	99.42	17.85	115	11462	168728	90448142
Epidural lipomatosis	89.16	17.85	17	11560	242	90616628
Hypertensive cardiomyopathy	86.44	17.85	17	11560	287	90616583
Cellulitis staphylococcal	67.28	17.85	17	11560	926	90615944
Short stature	65.15	17.85	17	11560	1053	90615817
Cushingoid	64.89	17.85	30	11547	10365	90606505
Lymphadenopathy	63.23	17.85	50	11527	45725	90571145
Interstitial lung disease	58.83	17.85	60	11517	76345	90540525
Actinomycotic sepsis	58.72	17.85	12	11565	248	90616622
Symptom recurrence	57.78	17.85	21	11556	3938	90612932
Juvenile idiopathic arthritis	53.98	17.85	20	11557	3957	90612913
Hepatosplenomegaly	51.64	17.85	18	11559	2991	90613879
Blood lactate dehydrogenase increased	50.87	17.85	35	11542	25897	90590973
Herpes zoster infection neurological	49.83	17.85	12	11565	535	90616335
Concomitant disease aggravated	47.31	17.85	25	11552	11493	90605377
Malaise	46.36	17.85	172	11405	585814	90031056
Focal nodular hyperplasia	45.72	17.85	12	11565	760	90616110
Cough	42.37	17.85	123	11454	368839	90248031
Drug reaction with eosinophilia and systemic symptoms	41.22	17.85	38	11539	42720	90574150
Epstein-Barr virus infection	41.21	17.85	22	11555	10322	90606548
C-reactive protein increased	41.20	17.85	79	11498	181310	90435560
Infusion related reaction	38.99	17.85	4	11573	416776	90200094
Chemokine increased	38.77	17.85	6	11571	21	90616849
Gastroenteritis	38.38	17.85	31	11546	29198	90587672
Graft versus host disease in gastrointestinal tract	38.19	17.85	16	11561	4372	90612498
Influenza	37.11	17.85	65	11512	139199	90477671
Arthralgia	36.84	17.85	196	11381	778326	89838544
Varicella zoster virus infection	36.67	17.85	15	11562	3862	90613008
Pneumonia lipoid	34.61	17.85	7	11570	137	90616733
Tonsillitis	34.04	17.85	17	11560	6952	90609918
Vitiligo	33.83	17.85	12	11565	2098	90614772
Autoimmune thyroiditis	33.67	17.85	16	11561	5877	90610993
Product supply issue	33.24	17.85	13	11564	2979	90613891
Chondrocalcinosis	33.15	17.85	11	11566	1574	90615296
Steroid dependence	32.98	17.85	12	11565	2257	90614613
Secondary adrenocortical insufficiency	32.73	17.85	12	11565	2306	90614564
Growth failure	32.70	17.85	8	11569	381	90616489
Hyperplasia	32.58	17.85	10	11567	1114	90615756
Systemic lupus erythematosus	32.52	17.85	4	11573	361892	90254978
Spinal fracture	32.46	17.85	25	11552	21991	90594879
Oropharyngeal pain	32.30	17.85	55	11522	115132	90501738
Rash	32.07	17.85	192	11385	795908	89820962
Pharyngitis streptococcal	31.81	17.85	20	11557	12722	90604148
Spondyloarthropathy	31.74	17.85	10	11567	1214	90615656
Drug hypersensitivity	31.54	17.85	10	11567	463599	90153271
Drug resistance	31.18	17.85	28	11549	30421	90586449
Obliterative bronchiolitis	31.03	17.85	12	11565	2669	90614201
Rhinorrhoea	29.99	17.85	46	11531	88270	90528600
Autoinflammatory disease	29.61	17.85	7	11570	288	90616582
SARS-CoV-2 test positive	29.13	17.85	18	11559	11110	90605760
Ileal ulcer	28.86	17.85	9	11568	1057	90615813
Synovitis	28.77	17.85	4	11573	329748	90287122
Immune thrombocytopenia	28.55	17.85	19	11558	13307	90603563
Blood creatine phosphokinase decreased	28.02	17.85	8	11569	694	90616176
Disease recurrence	27.94	17.85	29	11548	37624	90579246
Abdominal pain	27.81	17.85	112	11465	395609	90221261
Product storage error	27.71	17.85	22	11555	20219	90596651
Product use in unapproved indication	27.60	17.85	100	11477	336136	90280734
Amyloidosis	27.41	17.85	9	11568	1247	90615623
Hepatic steatosis	26.60	17.85	28	11549	36917	90579953
Arthropathy	26.56	17.85	7	11570	366235	90250635
Cutaneous symptom	25.63	17.85	7	11570	516	90616354
Alopecia	25.35	17.85	16	11561	495055	90121815
Cryopyrin associated periodic syndrome	25.06	17.85	7	11570	561	90616309
Drug ineffective for unapproved indication	24.45	17.85	36	11541	66608	90550262
Acute graft versus host disease in skin	24.41	17.85	12	11565	4744	90612126
Bacterial sepsis	23.95	17.85	12	11565	4943	90611927
Familial cold autoinflammatory syndrome	23.90	17.85	3	11574	0	90616870
Graft versus host disease in skin	23.67	17.85	11	11566	3842	90613028
Periodontal inflammation	23.43	17.85	4	11573	29	90616841
Syringe issue	23.27	17.85	11	11566	3991	90612879
Osteoporosis	23.08	17.85	43	11534	96488	90520382
Fall	22.76	17.85	17	11560	481793	90135077
Lymphocyte count decreased	22.49	17.85	25	11552	35025	90581845
Cytopenia	21.84	17.85	18	11559	17431	90599439
Hepatomegaly	21.56	17.85	16	11561	13310	90603560
Abdominal discomfort	21.09	17.85	18	11559	477310	90139560
Hypoaesthesia	20.96	17.85	7	11570	314203	90302667
Upper respiratory tract inflammation	20.79	17.85	9	11568	2663	90614207
Asteatosis	20.72	17.85	4	11573	61	90616809
Viral infection	20.71	17.85	26	11551	41388	90575482
Clostridium difficile colitis	20.59	17.85	21	11556	26685	90590185
Exposure during pregnancy	20.54	17.85	3	11574	238407	90378463
Type IV hypersensitivity reaction	20.43	17.85	10	11567	3916	90612954
Familial mediterranean fever	20.42	17.85	4	11573	66	90616804
Discomfort	20.35	17.85	5	11572	274330	90342540
Faecal calprotectin increased	20.29	17.85	10	11567	3977	90612893
Pharyngitis	20.17	17.85	19	11558	21928	90594942
Spinal stenosis	19.80	17.85	17	11560	17407	90599463
Wound	19.78	17.85	7	11570	302973	90313897
Splenomegaly	19.76	17.85	15	11562	12909	90603961
Nasal congestion	19.75	17.85	37	11540	83377	90533493
Rheumatoid arthritis	19.56	17.85	11	11566	362603	90254267
Gastrointestinal perforation	19.50	17.85	10	11567	4322	90612548
Sputum abnormal	18.71	17.85	6	11571	771	90616099
Quality of life decreased	18.62	17.85	14	11563	11875	90604995
Hyperferritinaemia	18.24	17.85	5	11572	374	90616496
Failure to thrive	18.04	17.85	12	11565	8399	90608471
Alveolar proteinosis	18.01	17.85	6	11571	870	90616000

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Apparent death	1023.97	26.90	231	11541	3477	42606086
Diverticulitis	679.46	26.90	250	11522	22523	42587040
Joint swelling	460.39	26.90	266	11506	67756	42541807
Pulmonary thrombosis	389.11	26.90	128	11644	8220	42601343
Red blood cell sedimentation rate increased	379.00	26.90	131	11641	9793	42599770
Inappropriate schedule of product administration	374.23	26.90	265	11507	95637	42513926
Deep vein thrombosis	369.96	26.90	242	11530	76715	42532848
Terminal state	311.50	26.90	93	11679	4330	42605233
Pulmonary embolism	305.41	26.90	257	11515	119355	42490208
C-reactive protein abnormal	254.95	26.90	96	11676	9165	42600398
Renal failure	253.50	26.90	251	11521	143475	42466088
Pain	244.60	26.90	318	11454	244530	42365033
C-reactive protein increased	179.40	26.90	145	11627	63415	42546148
Photosensitivity reaction	161.48	26.90	76	11696	12626	42596937
Haemophagocytic lymphohistiocytosis	160.57	26.90	85	11687	18137	42591426
Intestinal sepsis	160.27	26.90	38	11734	713	42608850
Joint arthroplasty	155.30	26.90	39	11733	938	42608625
Thrombosis	153.73	26.90	137	11635	68374	42541189
Arthropathy	122.46	26.90	85	11687	29512	42580051
Drug ineffective	121.28	26.90	414	11358	629783	41979780
Growth retardation	116.08	26.90	38	11734	2394	42607169
Contraindicated product administered	105.53	26.90	73	11699	25199	42584364
Pyrexia	104.46	26.90	290	11482	393752	42215811
Short stature	103.00	26.90	24	11748	416	42609147
Herpes zoster	101.83	26.90	85	11687	38792	42570771
Sepsis	90.15	26.90	181	11591	199153	42410410
Intentional product use issue	90.11	26.90	105	11667	71728	42537835
Interstitial lung disease	89.07	26.90	109	11663	78353	42531210
Stent placement	86.86	26.90	38	11734	5322	42604241
Illness	83.48	26.90	63	11709	24867	42584696
Stomatitis	83.03	26.90	85	11687	50244	42559319
Feeling abnormal	74.46	26.90	94	11678	69692	42539871
Knee arthroplasty	71.81	26.90	39	11733	8742	42600821
Spinal instability	70.87	26.90	19	11753	594	42608969
Urticaria	70.07	26.90	94	11678	73942	42535621
Cushingoid	67.86	26.90	28	11744	3394	42606169
Incorrect dose administered	65.67	26.90	77	11695	52897	42556666
Serum amyloid A protein increased	59.27	26.90	14	11758	258	42609305
Drug interaction	58.30	26.90	4	11768	266995	42342568
Juvenile idiopathic arthritis	57.14	26.90	23	11749	2616	42606947
Drug intolerance	55.54	26.90	88	11684	80336	42529227
Cellulitis	53.43	26.90	75	11697	61510	42548053
Toxicity to various agents	51.30	26.90	3	11769	229133	42380430
Muscle abscess	50.14	26.90	16	11756	928	42608635
Myocardial infarction	47.09	26.90	105	11667	123904	42485659
Pneumonia streptococcal	44.23	26.90	17	11755	1711	42607852
Nausea	43.67	26.90	28	11744	396771	42212792
Off label use	40.88	26.90	308	11464	638027	41971536
Osteopenia	40.82	26.90	24	11748	6254	42603309
Interleukin level increased	38.56	26.90	13	11759	897	42608666
Secondary adrenocortical insufficiency	37.67	26.90	16	11756	2083	42607480
Tonsillitis	36.37	26.90	17	11755	2774	42606789
Drug hypersensitivity	35.31	26.90	82	11690	99307	42510256
Condition aggravated	34.59	26.90	153	11619	260601	42348962
Hypotension	34.54	26.90	14	11758	257617	42351946
Vein disorder	34.37	26.90	15	11757	2087	42607476
Atlantoaxial instability	34.21	26.90	10	11762	431	42609132
Osteoporosis	33.73	26.90	30	11742	14876	42594687
Arthritis	33.20	26.90	49	11723	42016	42567547
Acute kidney injury	32.74	26.90	32	11740	367305	42242258
Hand fracture	32.69	26.90	16	11756	2890	42606673
Autoinflammatory disease	32.59	26.90	7	11765	82	42609481
Dyspnoea	32.53	26.90	45	11727	442576	42166987
Haemoglobin decreased	30.48	26.90	93	11679	132378	42477185
Secondary amyloidosis	29.24	26.90	7	11765	137	42609426
Foot fracture	28.47	26.90	19	11753	6172	42603391
Arthritis infective	27.49	26.90	16	11756	4090	42605473
Inflammatory marker increased	26.97	26.90	19	11753	6737	42602826

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Inappropriate schedule of product administration	593.76	18.65	383	17469	203254	110368193
Apparent death	453.25	18.65	103	17749	2799	110568648
Haemophagocytic lymphohistiocytosis	414.65	18.65	165	17687	31394	110540053
Pyrexia	359.01	18.65	569	17283	897696	109673751
Pulmonary thrombosis	321.01	18.65	110	17742	13753	110557694
Terminal state	296.78	18.65	84	17768	5583	110565864
Diverticulitis	239.69	18.65	133	17719	53389	110518058
Incorrect dose administered	200.66	18.65	152	17700	103489	110467958
Red blood cell sedimentation rate increased	200.18	18.65	136	17716	78166	110493281
C-reactive protein increased	156.23	18.65	184	17668	217735	110353712
Serum amyloid A protein increased	144.72	18.65	33	17819	909	110570538
Intestinal sepsis	137.33	18.65	32	17820	972	110570475
Interstitial lung disease	137.04	18.65	139	17713	139195	110432252
Growth retardation	129.44	18.65	37	17815	2545	110568902
Illness	125.73	18.65	105	17747	82066	110489381
Thrombosis	122.84	18.65	117	17735	108545	110462902
Photosensitivity reaction	118.37	18.65	65	17787	25524	110545923
Interleukin level increased	98.47	18.65	27	17825	1594	110569853
Sepsis	95.15	18.65	181	17671	327165	110244282
Joint arthroplasty	93.42	18.65	31	17821	3506	110567941
Deep vein thrombosis	91.77	18.65	113	17739	139774	110431673
Pulmonary embolism	89.14	18.65	139	17713	214335	110357112
Condition aggravated	83.34	18.65	284	17568	734552	109836895
Juvenile idiopathic arthritis	80.89	18.65	32	17820	5975	110565472
Clubbing	80.87	18.65	20	17832	785	110570662
Serum ferritin increased	80.54	18.65	39	17813	11808	110559639
Herpes zoster	80.03	18.65	93	17759	108286	110463161
COVID-19	79.34	18.65	142	17710	244918	110326529
Renal failure	74.25	18.65	132	17720	226442	110345005
Stent placement	68.57	18.65	30	17822	7204	110564243
Secondary adrenocortical insufficiency	68.14	18.65	26	17826	4408	110567039
C-reactive protein abnormal	66.76	18.65	93	17759	129602	110441845
Symptom recurrence	66.28	18.65	26	17826	4746	110566701
Autoinflammatory disease	62.06	18.65	14	17838	367	110571080
Cellulitis	61.36	18.65	88	17764	125928	110445519
Tonsillitis	58.75	18.65	28	17824	8185	110563262
Influenza	57.28	18.65	100	17752	169001	110402446
Concomitant disease aggravated	55.54	18.65	34	17818	16330	110555117
Lymphadenopathy	52.58	18.65	58	17794	63777	110507670
Cellulitis staphylococcal	52.36	18.65	16	17836	1387	110570060
Drug interaction	52.14	18.65	9	17843	500174	110071273
Muscle abscess	51.63	18.65	16	17836	1453	110569994
Hepatosplenomegaly	47.70	18.65	23	17829	6896	110564551
Product supply issue	46.92	18.65	19	17833	3767	110567680
Actinomycotic sepsis	46.91	18.65	10	17842	200	110571247
Urticaria	46.84	18.65	135	17717	318722	110252725
Feeling abnormal	46.46	18.65	95	17757	180616	110390831
Chemokine increased	43.71	18.65	7	17845	24	110571423
Pneumonia streptococcal	41.50	18.65	17	17835	3472	110567975
Drug ineffective	41.48	18.65	400	17452	1520140	109051307
Cushingoid	41.46	18.65	25	17827	11687	110559760
Myocardial infarction	41.37	18.65	94	17758	191989	110379458
Hypertensive cardiomyopathy	40.75	18.65	10	17842	380	110571067
Joint swelling	39.81	18.65	159	17693	442686	110128761
Product use in unapproved indication	39.71	18.65	160	17692	447217	110124230
Arthralgia	39.21	18.65	237	17615	779395	109792052
Toxicity to various agents	38.04	18.65	15	17837	480540	110090907
Herpes zoster infection neurological	37.81	18.65	10	17842	514	110570933
Pneumonia	37.63	18.65	256	17596	876458	109694989
Pain	37.58	18.65	273	17579	954682	109616765
Varicella zoster virus infection	37.46	18.65	19	17833	6349	110565098
Oropharyngeal pain	37.01	18.65	73	17779	135203	110436244
Cough	36.98	18.65	160	17692	461481	110109966
Gastroenteritis	36.80	18.65	38	17814	38762	110532685
Secondary amyloidosis	36.77	18.65	9	17843	338	110571109
Disease recurrence	36.48	18.65	47	17805	60737	110510710
Nausea	35.83	18.65	93	17759	1235597	109335850
Familial mediterranean fever	35.82	18.65	8	17844	200	110571247
Steroid dependence	35.04	18.65	20	17832	8449	110562998
Synovitis	33.22	18.65	3	17849	274089	110297358
Drug ineffective for unapproved indication	32.47	18.65	59	17793	102779	110468668
Focal nodular hyperplasia	32.32	18.65	10	17842	903	110570544
Otitis media	31.86	18.65	18	17834	7458	110563989
Upper respiratory tract inflammation	31.56	18.65	15	17837	4356	110567091
Osteoporosis	31.41	18.65	53	17799	87099	110484348
Pharyngitis streptococcal	31.39	18.65	22	17830	13255	110558192
Short stature	30.61	18.65	10	17842	1077	110570370
Hypoaesthesia	29.91	18.65	7	17845	314216	110257231
Inflammatory marker increased	29.69	18.65	22	17830	14447	110557000
Blood lactate dehydrogenase increased	29.34	18.65	36	17816	44298	110527149
Chondrocalcinosis	28.22	18.65	11	17841	1974	110569473
Haemoglobin decreased	27.92	18.65	96	17756	248631	110322816
Hyperplasia	27.34	18.65	10	17842	1508	110569939
Spondyloarthropathy	26.74	18.65	10	17842	1604	110569843
Hyperferritinaemia	26.65	18.65	9	17843	1074	110570373
Vein disorder	26.46	18.65	15	17837	6255	110565192
Rhinorrhoea	26.40	18.65	54	17798	102612	110468835
Pericardial calcification	26.33	18.65	5	17847	54	110571393
Autoimmune thyroiditis	26.10	18.65	15	17837	6419	110565028
Systemic lupus erythematosus	25.57	18.65	5	17847	254333	110317114
Hand fracture	25.35	18.65	16	17836	8106	110563341
Dyspnoea	25.16	18.65	93	17759	1106779	109464668
SARS-CoV-2 test positive	24.56	18.65	21	17831	16914	110554533
Pharyngitis	24.56	18.65	25	17827	25073	110546374
Epidural lipomatosis	24.34	18.65	10	17842	2057	110569390
Viral infection	24.23	18.65	36	17816	53103	110518344
Drug resistance	24.02	18.65	37	17815	56337	110515110
Arthritis infective	24	18.65	17	17835	10412	110561035
Hypotension	23.56	18.65	30	17822	523819	110047628
Asteatosis	23.40	18.65	6	17846	273	110571174
Amyloidosis	23.23	18.65	11	17841	3170	110568277
Faecal calprotectin increased	22.90	18.65	14	17838	6705	110564742
General physical health deterioration	22.84	18.65	21	17831	425274	110146173
Cryopyrin associated periodic syndrome	22.78	18.65	7	17845	618	110570829
Lymph nodes scan abnormal	21.71	18.65	5	17847	144	110571303
Upper respiratory tract infection	21.61	18.65	58	17794	131270	110440177
Blood creatine phosphokinase decreased	21.30	18.65	8	17844	1299	110570148
Periodontal inflammation	21.16	18.65	4	17848	42	110571405
Subcutaneous abscess	21.01	18.65	15	17837	9302	110562145
Alopecia	20.81	18.65	17	17835	364736	110206711
Vitiligo	20.71	18.65	10	17842	3007	110568440
Vascular cognitive impairment	20.68	18.65	4	17848	48	110571399
Staphylococcal infection	20.66	18.65	39	17813	69905	110501542
Death	20.65	18.65	52	17800	698817	109872630
Peripheral swelling	20.48	18.65	21	17831	404013	110167434
Depression	20.44	18.65	13	17839	317322	110254125
Cutaneous symptom	20.39	18.65	7	17845	878	110570569
Infusion related reaction	20.25	18.65	19	17833	381143	110190304
Arthritis	19.96	18.65	66	17786	167520	110403927
Rash	19.83	18.65	211	17641	820753	109750694
Asthenia	19.79	18.65	52	17800	688947	109882500
Sleep disorder	19.76	18.65	4	17848	198640	110372807
Paraesthesia	19.71	18.65	10	17842	276511	110294936
Superinfection bacterial	19.70	18.65	9	17843	2392	110569055
Rheumatoid arthritis	19.68	18.65	12	17840	299601	110271846
Muckle-Wells syndrome	19.58	18.65	3	17849	7	110571440
Helicobacter infection	19.54	18.65	3	17849	181874	110389573
Inflammatory bowel disease	19.50	18.65	13	17839	7221	110564226
Gene mutation	19.50	18.65	10	17842	3419	110568028
Somnolence	19.41	18.65	12	17840	297437	110274010
Quality of life decreased	19.39	18.65	17	17835	14152	110557295
Abdominal discomfort	19.37	18.65	21	17831	393837	110177610
Fall	19.34	18.65	43	17809	603439	109968008
Graft versus host disease in gastrointestinal tract	19.22	18.65	14	17838	8954	110562493
Oedema peripheral	19.15	18.65	15	17837	328645	110242802
Overdose	18.97	18.65	7	17845	233787	110337660
Epstein-Barr virus infection	18.95	18.65	19	17833	18719	110552728
Ileal ulcer	18.74	18.65	8	17844	1809	110569638
Obliterative bronchiolitis	18.72	18.65	10	17842	3713	110567734

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L04AC08	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Interleukin inhibitors
CHEBI has role	CHEBI:22587	antiviral agent
CHEBI has role	CHEBI:33281	antimicrobial agent
CHEBI has role	CHEBI:35526	hypoglycemic agent
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:35842	antirheumatic drug
CHEBI has role	CHEBI:35845	gout suppressant
CHEBI has role	CHEBI:38070	anti-arrhythmia drug
CHEBI has role	CHEBI:66981	ophthalmology drug
CHEBI has role	CHEBI:67079	anti-inflammatory agent
CHEBI has role	CHEBI:75835	anti-anaemic agent
CHEBI has role	CHEBI:76916	hyperglycemic agent
CHEBI has role	CHEBI:145947	antiatherosclerotic agent

Related Drugs by ATC class:

L04AC Interleukin inhibitors 18 drugs

anakinrabasiliximabbimekizumabbrodalumabdaclizumabguselkumabixekizumabmirikizumabrilonaceptrisankizumabsarilumabsatralizumab show all 18 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Familial Mediterranean fever	indication	12579009	DOID:2987
Articular gout	indication	48440001	DOID:13189
Deficiency of mevalonate kinase	indication	124327008	DOID:0050452
Systemic onset juvenile chronic arthritis	indication	201796004
TNF receptor-associated periodic fever syndrome (TRAPS)	indication	403833009
Cryopyrin associated periodic syndrome	indication	430079001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Interleukin-1 beta	Cytokine	P01584	IL1B_HUMAN	ANTIBODY BINDING				DRUG LABEL	DRUG LABEL

External reference:

ID	Source
D09315	KEGG_DRUG
4028805	VUID
N0000178497	NUI
4028805	VANDF
CHEBI:749608	CHEBI
CHEMBL1201834	ChEMBL_ID
C541220	MESH_SUPPLEMENTAL_RECORD_UI
6773	IUPHAR_LIGAND_ID
DB06168	DRUGBANK_ID
853491	RXNORM
165731	MMSL
26503	MMSL
d07451	MMSL
013212	NDDF
698091001	SNOMEDCT_US
703376008	SNOMEDCT_US
C2718773	UMLSCUI
8836	INN_ID
37CQ2C7X93	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Ilaris	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0734	INJECTION, SOLUTION	150 mg	SUBCUTANEOUS	BLA	32 sections